Switching from IV to SC infliximab: insights from RW study [Podcast]

Dr Philip Smith from The Royal Liverpool Hospital / UK discusses his recently published study of a managed switch program from maintenance intravenous infliximab to subcutaneous infliximab in patients with inflammatory bowel disease during the COVID pandemic. In conversation with Queensland gastroenterologist Dr Yoon An, Dr Smith explains how these results can inform a switch to subcutaneous infliximab beyond pandemic times.

Dr Simon Ghaly (St Vincent's Hospital, Sydney) on The Move towards Subcut versions of established biologics

Dr Philip J Smith (The Royal Liverpool Hospital / UK) on Real World Experience in switching to Subcut Infliximab

A/Prof Britt Christensen (The Royal Melbourne Hospital) on New Options in Subcut Therapies for fistulising Crohn's Disease

RA Educational Meeting Video